These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22193644)

  • 1. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.
    Yin M; Lou C; Zhang W; Meng F; Zhang H; Ning X; Zhou R; Dong X; Lou G
    Int J Gynecol Cancer; 2012 Jan; 22(1):54-62. PubMed ID: 22193644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
    Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
    Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
    Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocyte elevated gene-1: a novel independent prognostic biomarker for metastatic ovarian tumors.
    Li C; Chen K; Cai J; Shi QT; Li Y; Li L; Song H; Qiu H; Qin Y; Geng JS
    Tumour Biol; 2014 Apr; 35(4):3079-85. PubMed ID: 24234336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
    Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
    Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis.
    Yin M; Xu Y; Lou G; Hou Y; Meng F; Zhang H; Li C; Zhou R
    Int J Cancer; 2011 Aug; 129(3):629-35. PubMed ID: 20857494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
    Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
    PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
    Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
    Meng F; Tan S; Liu T; Song H; Lou G
    Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
    Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
    PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated lysosome-associated protein transmembrane-4β-35 is an independent prognostic marker in pancreatic carcinoma.
    Zhang G; Liang Y; Huang Y; Chen Y; Zhou R
    J Int Med Res; 2012; 40(4):1275-83. PubMed ID: 22971479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma.
    Kang Y; Yin M; Jiang W; Zhang H; Xia B; Xue Y; Huang Y
    Am J Surg; 2012 Nov; 204(5):677-83. PubMed ID: 22578410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
    Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
    Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
    Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
    Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of LAPTM4B and p27kip1 expression in triple-negative breast cancer.
    Li X; Song C; Wang K; Li N; Sun S; Li N; Zhao Z; Li M
    Cancer Biomark; 2019; 25(1):19-27. PubMed ID: 31033460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
    Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
    J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.
    Cheng X; Tian X; Wu X; Xing X; Du H; Zhou C; Zhang Q; Hao C; Wen X; Ji J
    PLoS One; 2016; 11(7):e0158715. PubMed ID: 27391361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
    Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
    Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.